Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy.

Journal Information

Full Title: Acta Neuropathol

Abbreviation: Acta Neuropathol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestAEL has served as an advisor for AbbVie, AFFiRis, Alector, Amylyx, Aprinoia, Biogen, BioAdvance, BlueRock, Biovie, BMS, CoA Therapeutics, Denali, Janssen, Jazz, Lilly, Novartis, Paladin, Pharma 2B, PsychoGenetics, Retrophin, Roche, Sun Pharma, and UCB; received honoraria from Sun Pharma, AbbVie and Sunovion; received grants from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, Parkinson Foundation, Parkinson Canada, and W. Garfield Weston Foundation; is serving as an expert witness in litigation related to paraquat and Parkinson’s disease, received publishing royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press. GGK is member of the Acta Neuropathologica Editorial Board but was not involved in the editorial handling of this article. GGK has served as an advisor for Biogen; received royalty for 5G4 synuclein antibody and publishing royalties from Wiley, Cambridge University Press and Elsevier, received grants from Edmond J Safra Philanthropic Foundation, Rossy Foundation, Michael J. Fox Foundation, Parkinson Canada, Canada, Canada Foundation for Innovation, MSA Coalition, and National Institutes of Health (NIH). SLF, SL, NN, IMV, VS, JL, AA, MCT, LI, MU have no declarations of interest. Conflict of interest AEL has served as an advisor for AbbVie, AFFiRis, Alector, Amylyx, Aprinoia, Biogen, BioAdvance, BlueRock, Biovie, BMS, CoA Therapeutics, Denali, Janssen, Jazz, Lilly, Novartis, Paladin, Pharma 2B, PsychoGenetics, Retrophin, Roche, Sun Pharma, and UCB; received honoraria from Sun Pharma, AbbVie and Sunovion; received grants from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, Parkinson Foundation, Parkinson Canada, and W. Garfield Weston Foundation; is serving as an expert witness in litigation related to paraquat and Parkinson’s disease, received publishing royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press. GGK is member of the Acta Neuropathologica Editorial Board but was not involved in the editorial handling of this article. GGK has served as an advisor for Biogen; received royalty for 5G4 synuclein antibody and publishing royalties from Wiley, Cambridge University Press and Elsevier, received grants from Edmond J Safra Philanthropic Foundation, Rossy Foundation, Michael J. Fox Foundation, Parkinson Canada, Canada, Canada Foundation for Innovation, MSA Coalition, and National Institutes of Health (NIH). SLF, SL, NN, IMV, VS, JL, AA, MCT, LI, MU have no declarations of interest."

Evidence found in paper:

"Funding Open Access funding enabled and organized by CAUL and its Member Institutions."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025